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Objective: To review the epidemiology, risk factors for, treatment and outcome of ventilator-
associated sinusitis (VAS).
Methods: We performed a systematic review and meta-analysis of available data without time
restrictions. A conservative random effects model was employed to calculate pooled odds
ratios (OR) and 95% confidence intervals (CIs).
Results: Out of 620 retrieved reports, 31 papers fulfilled our inclusion criteria. Infectious sinus-
itis affects 27% of mechanically ventilated patients and was found to be the cause of undeter-
mined fever in 25% of the cases. Although radiographic VAS was higher in nasotracheally
compared to orotracheally intubated patients (OR 4.66, 95% CI 1.35e16.13), clinical VAS was
not (3.67, 0.80e6.81). The presence of VAS has been associated with the presence of VAP
(3.66, 1.81e7.37) or bacteremia (6.85, 2.14, 21.92); however, it is unknown whether an etio-
logic relationship between them exists. In patients with concomitant VAS and VAP or blood-
stream infections identical pathogens are isolated in 59% and 20% of the cases, respectively.
The presence as opposed to absence of VAS was not associated with excess mortality (1.02,
0.35e3.01).
Conclusion: VAS is a common infection in critically ill adults and correlates with other impor-
tant infectious complications.
ª 2012 Elsevier Ltd. All rights reserved.e of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. Tel.: þ30 694
gr, matthew.falagas@tufts.edu (M.E. Falagas).
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Ventilator-associated sinusitis (VAS) is an infectious
complication of endotracheally intubated critically ill
patients, which was first recognized and described by Arens
in a case series of four nasotracheally intubated post
operative patients.1 The years that followed Arens’ original
report witnessed an upsurge of scientific interest in the
field of paranasal sinuses infections in the critically ill and
lead to accumulation of substantial evidence regarding
issues as pathogenesis, predisposing factors, diagnosis,
clinical presentation and management.2,3 As a result,
nowadays VAS is regarded a potential cause of cryptic fever
or sepsis in the critically ill patients4 and has been impli-
cated as risk factor for ventilator-associated pneumonia
(VAP) in guidelines endorsed by scientific societies.5,6
On the other hand, during the last decades, scientific
interest has almost consistently focused on lower respira-
tory tract infections in the critically ill, mainly VAP5,7,8 and
most recently ventilator-associated tracheobronchitis.8,9
Less emphasis has been given to upper respiratory tract
infections and despite the accumulated evidence, several
key issues, as VAS incidence in critically ill patients, role of
nasal instrumentation in its pathogenesis, relationship to
other infectious complications, optimal prevention and
treatment strategies, as well as its impact on outcome
remain largely controversial or unresolved.2,3 Considering
the significant impact of respiratory tract infections on the
morbidity and mortality of the critically ill,9e12 we under-
took this systematic review and meta-analysis in order to
review the epidemiology, risk factors for, treatment and
outcome of ventilator-associated sinusitis.Methods
Search strategy
Two reviewers (MA and IDG) independently performed
literature search, study identification and data extraction.
Any disagreement between the two reviewers was resolved
by consensus in meetings of all authors. We searched
PubMed and Scopus databases up to February 2011 using
the following key terms: (ventilator OR nosocomial OR
ventilator-associated OR ICU OR critical care) AND sinus-
itis. We also hand searched the reference lists of the
initially retrieved papers and of relevant review articles. No
restriction was set regarding the time of publication. Only
papers in English were included. Abstracts presented in
international conferences were not searched.Definitions
Radiographic VAS (R-VAS) was defined as the presence of
complete opacification or an air fluid level in CT (or MRI)
scan or in sinus plain radiograph or the presence of fluid
identified by ultrasound sinus examination in a patient on
mechanical ventilation for >48 h.
Clinical VAS (C-VAS) was defined based on the presence
of R-VAS plus all of the following: (i) fever (>38 C) or
hypothermia (<36 C), (ii) leukocytosis (>10 000/mL) or
leukopenia (<4000/mL) (iii) purulent sinus fluid. A positive
sinus fluid culture or more than 5 neutrophils in the
microscopic sinus fluid examination was not a pre-requisite
for inclusion.
1084 M. Agrafiotis et al.VAP was defined based on the presence of a new or
evolving infiltrate in the chest radiograph in patients on
mechanical ventilation for >48 h, plus the following: (i)
fever (>38 C) or hypothermia (<36 C), (ii) leukocytosis
(>10 000/mL) or leukopenia (<4000/mL) (iii) purulent
tracheal secretions and/or (iv) a microbiologically positive
respiratory sample.
Study selection and data extraction
A paper was considered eligible for inclusion into the
review if it reported data on R-VAS C-VAS incidence, risk
factors, prevention, treatment, outcome, complications,
as well as VAS relationship to other infections in the criti-
cally ill. Case-reports/series, data reported in form of
letters, laboratory/experimental studies, and studies on
neonatal/pediatric populations were not included. From
each eligible paper the following data were extracted:
first author, year of publication, study setting and
design, number and demographics of participants,
frequency of R-VAS and C-VAS, routes of tracheal and
gastric intubation, implicated pathogens and method of
microbiological confirmation, preventional or therapeutic
interventions, mortality of patients with VAS and frequency
and implicated pathogens of other infections in patients
with VAS.
Statistical methods and data analysis
Review Manager (RevMan; Copenhagen: Nordic Cochrane
Center, Cochrane Collaboration) was used for the statistical
analysis. Heterogeneity among the results of the included
papers was evaluated by using both the I2-statistic and the
chi-squared test; a p value <0.1 was considered statisti-
cally significant in the assessment of heterogeneity. Pooled
odds ratios and 95% confidence intervals were calculated by
employing the conservative DerSimonianeLaird random
effects model.
Results
Characteristics of the selected articles
The process employed to identify potentially relevant
articles is presented in detail in Fig. 1. Out of 620 articles
retrieved, 31 articles13e43 fulfilled the inclusion criteria of
this review. In detail, we identified 22
cohorts,13,15,17,20e24,26e32,35,36,38,40e43 8 randomized
controlled trials14,16,18,25,33,34,37,39 and 1 retrospective
analysis19 of data obtained in a previously published
randomized controlled trial44 (Tables 1e5). Patients with
a history of sinus disease, facial or sinus trauma were
excluded in 18 of these studies.13e17,21e23,26e28,31,34,36e39,43
Frequency of VAS in the general population of
critically ill patients
Five eligible studies,25,29,31,38,40 involving in total 524
subjects, were specifically designed to systematically
investigate the incidence of VAS in critically ill patients(Table 1). The average frequency of R-VAS in these studies
was estimated to 56% (median 55%, range [18e88]). In
addition, 3 of them (461 patients) reported data on the
relationship between R-VAS and C-VAS.25,29,31 Overall, the
mean frequency of R-VAS in this population was estimated
to be 57% (median 55%, range [18e82]). The average
frequency of C-VAS in patients with R-VAS was 51% (median
56%, range [38e73]); the corresponding figure in the total
population was 27% (median 31%, range [1e40]).
Incidence of VAS in critically ill patients with fever
of undetermined origin
Data on the incidence of VAS in critically ill patients with
fever of undetermined origin were provided by 13 studies
involving 1155 patients (Table
2).13,15,17,20,23,26e28,32,36,41e43 The average frequency of R-
VAS in 8 studies from which data could be extracted (715
patients) was 39% (median 61%, range
[11e77]).13,15,17,20,23,27,36,43 The average frequency of C-
VAS in 12 studies (1073 patients) was 25% (median 24%,
range [3e53]).13,15,17,23,26e28,32,36,41e43
Microbiology
Twenty-two studies13,15e17,21e25,27e32,34,35,37,39,41e43
provided quantitative data on the pathogens implicated in
episodes of C-VAS, for a total of 1470 isolates. Gram-
negative aerobic pathogens accounted for the majority of
them (49%), followed by Gram-positive aerobic pathogens
(37%), fungi (7.5%) and anaerobes (7.5%). Pseudomonas spp
(13%) and Streptococcus spp (including Streptococcus
pneumoniae) (13%) were the most commonly isolated
pathogens; other culprit microorganisms were Staphylo-
coccus aureus (11%), Escherichia coli (9%), coagulase-
negative staphylococci (6%), Acinetobacter spp (5%) and
Klebsiella spp (5%). According to the results of 11 stud-
ies,21,25,27,28,31,34,37,39,41e43 C-VAS is a polymicrobial infec-
tion in 54% out of 327 patients.
Risk factors for VAS
Two reports attempted to identify potential risk factors for
C-VAS.27,31 In a multiple logistic regression model by George
et al,.27 nasal colonization with Gram-negative bacilli,
feeding by nasoenteric tube, sedative use and a Glasgow
Coma Scale score less than 7, were the factors indepen-
dently associated with a higher risk for C-VAS. On the other
hand, in a stepwise logistic regression analysis by Rouby
et al.,31 nasal placement of tracheal tube and gastric tube
and their respective durations were the identified inde-
pendent risk factors for R-VAS.
Role of nasal instrumentation in the incidence of
VAS
Four eligible studies, involving in total 412 subjects,
provided data on the development of VAS in nasotracheally
as opposed to orotracheally intubated patients (Table 3).
When the results of these studies are considered together
Potentially relevant articles retrieved from 
PubMed and Scopus search (n=620)
Articles excluded (n=394) because: 
-Were irrelevant to our subject (n=143). 
-Were written in French (n=36), German (n=26), Spanish (n=9), 
Russian (n=5), Polish (n=4), Italian (n=3), Danish (n=2), Turkish 
(n=1), Croatian (n=1), Czech (n=1), Portuguese (n=1). 
-Were reviews (n=171), guidelines (n=11), abstracts (n=5)
Articles excluded (n=139) because: 
-Referred to nosocomial sinusitis or patient ventilation status was 
unspecified (n=20). 
-Were letters/comments (n=19), case reports/series (n=10). 
-Referred to surgical management issues (n=14). 
-Referred to community-acquired infectious sinusitis (n=12), 
sinusitis in immunecompromised patients (n=13), allergy- related 
sinusitis (n=5), autoimmune disease-related sinusitis (n=4), sinusitis 
in cystic fibrosis patients (n=2). 
-Compared imaging modalities (n=14). 
-Were experimental/laboratory studies (n=11). 
-Referred to paediatric populations (n=6). 
-Were surveillance studies (n=4). 
-Sinusitis definition was not specified (n=2). 
2 articles were retrieved from 
search of relevant 
bibliographies 
29 articles were selected for 
inclusion in this review 
Figure 1 Flow diagram of the reviewed articles.
Ventilator-associated sinusitis 1085the frequency of R-VAS is higher in nasotracheally intu-
bated patients (OR 4.66, 95% CI [1.35, 16.13], I2 Z 75%)
(Fig. 2). In addition, 3 of the abovementioned studies also
studied the development of C-VAS among nasotracheallyand orotracheally intubated patients.34,35,37; there was no
difference in the frequency of C-VAS between the
compared groups (OR 3.67, 95% CI [0.80, 16.81], I2 Z 77%)
(Fig. 3).
Table 1 Studies designed to systemically investigate the incidence of VAS in critically ill patients.
Author name/
year/ref
Number
of pts
Setting Design/number
of centers
Study
population
Mode of investigation Cultu OTI NTI Number of
patients with
R-VAS (%)
Number of
patients
with C-VAS (%)
1 Holzapfel/199925 199 General ICU Prospective
RCT/SC
PTS on MV
> 48 h
Repeated sinus CT
in pts with
temperature
> 38 C
Quan
cultu
obta
max
punc
0 199 110/199 (56) 80/199 (40)
2 Kaups/199529 100 Surgical ICU Prospective
cohort/ SC
Pts on
prolonged MV
Sinus US on admission
and every 48 h
Cultu
obta
max
punc
72 18 18/100 (18) 1/100 (1)
3 Pedersen/199138 47 General ICU Prospective
cohort/SC
Pts on MV
for>5 days
SXR on day 5 NR 0 47 19/47 (40) NR
4 Rouby/199131 162 Surgical ICU Prospective
cohort/SC
Pts on MV
for >1 h
to 12 days
Sinus CT in 48 h and
after 7 days
Quan
cultu
obta
max
punc
97 65 133/162 (82) 51/162 (31)
5 Fassoulaki/198940 16 General ICU Prospective
cohort/SC
Pts on
prolonged MV
Sinus CT between
days 2 and 3 and
on day 8
NR 0 16 14/16 (88) NR
Abbreviations: CT: computerized tomography; C-VAS: clinical ventilator-associated sinusitis; ICU: intensive care unit; MV: m ventilation; NR: not reported; NTI: nasotracheal
intubation; OTI: orotracheal intubation; Pts: patients; RCT: randomized controlled trial; R-VAS: radiographic ventilator-a inusitis; SC: single center; SXR: sinus X-ray; US:
ultrasound.
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Table 2 Studies reporting on the incidence of VAS in critically ill patients with fever of undetermined origin.
Author name/
year/ref
Number
of pts
Setting Design/Number
of centers
Study population Imaging Cultures OTI NTI Number of
patients
with R-VAS (%)
Number of
patients with
C-VAS (%)
1 Cengiz/200913 40 General ICU Prospective
cohort/SC
Head trauma pts on
MV > 2 days
CT/US Quantitative; cu res
obtained by ma ary
puncture
40 0 28/40 (70) 13/40 (32)
2 Vargas/200615 60 Medical ICU Prospective
cohort/SC
Pts on MV > 2 days US Quantitative; cu res
obtained by ma ary
puncture
NR NR 46/60 (77) 26/60 (43)
3 van Zanten/
200517
198 General ICU Prospective
cohort/SC
Pts on MV > 2days SXR Semiquantitativ
cultures obtaine by
maxillary punct
111/198 (56) 105/198 (53)
4 McCormick/
200320
84 Burns ICU Retrospective
cohort/SC
Pts on MV > 7 days CT NR 84 0 13/84 (15) NR
5 Suweine/
200023
36 MedicaleSurgical
ICU
Prospective
cohort/SC
Pts on MV > 3days CT Quantitative; cu res
obtained by ma ary
puncture
22 2 24/36 (67) 15/36 (42)
6 George/199827 230 Medical ICU Prospective
cohort/MC
Pts on MV > 2 days (2) CT Cultures obtaine by
maxillary punct
228 0 24/230 (11) 28/230 (12)
7 Westergren/
199826
33 General/
Neurosurgical ICU
Prospective
cohort/SC
Pts on MV > 7 days CT Cultures obtaine by
antroscopy
1 20 NR 3/33 (9)
8 Spapen/
199528
38 General ICU Retrospective
cohort/SC
Pts on MV > 7 days CT Semiquantitativ
cultures obtaine by
maxillary punct
13 0 NR 13/38 (34)
9 Meduri/199432 50 Medical ICU Prospective
cohort/SC
Pts on MV > 2 days CT NR NR NR NR 12/50 (24)
10 Borman/199236 26 Surgical ICU Prospective
cohort/SC
Pts on MV > 2 days US Cultures obtaine
by maxillary pun ure
NR 20 19/26 (73) 1/26 (4)
12 Humphrey/
198741
208 Neurosurgical ICU Retrospective
cohort/SC
Head trauma pts on
prolonged MV
CT Cultures obtaine by
antral puncture d
open ethmoidec my/
sphenoidectomy
NR NR NR 24/208 (12)
13 Grindlinger/
198742
111a Neurosurgical ICU Prospective
cohort/SC
Head trauma pts on
prolonged MV(5)
CT Cultures obtaine by
antral puncture d
open ethmoidec my
or sphenoidecto
65 31 NR 19/111 (17)
14 Deutschman/
198543
43 Neurosurgical ICU Retrospective
cohort/SC
Pts on MV > 3 days CT/SXR Cultures obtaine by
antral puncture
0 43 11/43 (26) 10/43 (23)
Abbreviations: CT: computerized tomography; C-VAS: clinical ventilator-associated sinusitis; ICU: intensive care unit; MC: multi cen ; MV: mechanical ventilation; NR: not reported; NTI:
nasotracheal intubation; OTI: orotracheal intubation; Pts: patients; R-VAS: radiographic ventilator-associated sinusitis; SC: single nter; SXR: sinus X-ray; US: ultrasound.
Notes:
a Fifteen pts were not intubated; 75 pts were intubated for more than 2 days.
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Table 3 Randomized controlled trials reporting on the frequency of VAS in nasotracheally versus orotracheally in tients.
Author name/
year/ref
Number
of pts
Setting Design/number
of centers
Study population Mode of
investigation
Cu OTI NTI Number
of patients
with R-VAS (%)
Number of
patients with
C-VAS (%)
1 Holzapfel/199334 300 General ICU RCT/SC Pts on MV > 2 days Sinus CT every
7 days
Qu
cu
ob
ma
pu
151 149 78/300 (26) 54/300 (18)
2 Bach/199237 68 Surgical ICU RCT/SC Pts on MV > 4 days SXR on days 4,7,
10 and weekly
Qu
cu
ob
ma
pu
32 36 40/68 (59) 17/68 (25)
3 Michelson/199235 44 Surgical ICU RCT/SC Pts on prolonged MV Daily sinus US Cu
ob
ma
pu
24 20 34/44 (77) 9/44 (20)
4 Salord/199039 111 General ICU RCT/SC Pts on prolonged MV SXR on days 3,7
and weekly
Cu
ob
ma
pu
53 58 26/111 (23) NR
Abbreviations: CT: computerized tomography; C-VAS: clinical ventilator-associated sinusitis; ICU: intensive care unit; MV l ventilation; NR: not reported NTI: nasotracheal
intubation; OTI: orotracheal intubation; Pts: patients; RCT: randomized controlled trial; R-VAS: radiographic ventilator- inusitis; SC: single center; SXR: sinus X-ray; US:
ultrasound.
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Table 4 Studies reporting on the effects of preventive measures on the incidence of VAS.
Author name/
year/ref
Number
of pts
Setting Design/
Number
of centers
Study
population
Study
group
Control
group
Intervention Control Imaging Cultures R-VAS/
study
group (%)
C-VAS/
study
group (%)
R-VAS/
control
group (%)
C-VAS/
control
group (%)
1 Seder/201014 80 Surgical
ICU
RCT/SC Pts requiring
nasojejunal
feeding
40a 40a Nasal bridling Standard
care
CT NR 0/40 (0) NR 2/40 (5) NR
2 Pneumatikos/
200616
79 General
ICU
RCT/MC Trauma pts
on MV
> 3 days
39 40 Nasal
xylometazoline
þ budesonide
No
treatment
CT Quantitative;
cultures
obtained by
maxillary
puncture
21/39 (54) 3 (7) 33 (80) 8/40 (2)
3 Camus/200518 516 General
ICU
RTC/MC Pts on MV
> 2 days
129 387b Polymyxin
E and
tobramycin
(nasally,
oropharyngeally
and via the
gastric tube)
combined with
mupirucin
(nasally)
and chlorexidine
(body washing)
Either
regimen
alone or
placebo
CT Quantitative;
cultures
obtained by
maxillary
puncture
NR 3/129
(2.3)
NR 8/130
(6.2)c vs.
7/130
(5.4)d vs.
4/126
(3.2)e
4 Schweickert/
200419
126 Medical
ICU
RCT/SCf Pts on MV
> 2 days
66 60 Daily interruption
of sedative
infusions
Physician
directed
sedation
protocol
CT NR 0 (0) 1/60 (2)
5 Korinek/199333 123 Neurosurgical
ICU
RCT/MC Pts on MV
> 5 days
63 60 Polymyxin E,
tobramycin,
amphotericin
B via the gastric
tube plus
oral vancomycine
Placebo CT Cultures
obtained by
maxillary
puncture
NR 2/63 (3) NR 9/60 (15)
Abbreviations: CT: computerized tomography; C-VAS: clinical ventilator-associated sinusitis; ICU: intensive care unit; MC: multi center; MV: mechanical ventilation; NR: not reported; Pts:
patients; RCT: randomized controlled trial; R-VAS: radiographic ventilator-associated sinusitis; SC: single center.
Notes:
a Thirty-three patients were on MV.
b Control patients were divided into three subgroups: placebo (n Z 127), Polymin/Tobramycin (n Z 130), Mupirucin/Chlorexidine (n Z 130).
c Polymin/Tobramycin subgroup.
d Mupirucin/Chlorexidine subgroup.
e Placebo.
f Retrospective analysis of data obtained in the RCT by Kress et al.35
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Table 5 Other eligible studies reporting on VAS in critically ill patients.
Author name/
year/ref
Setting Design/number
of centers
Study
population
Number of
patients
Imaging Cultures Num of
pat s with
R-V %)
Number
of patients
with
C-VAS (%)
Comment
1 Casiano/200121 General
ICU
Prospective
cohort/SC
Pts on
prolonged MV
20a CT Quantitative;
cultures
obtained by
maxillary
puncture and
endoscopically
NR 18/20 (90) Comparison of
microbiological
results between
maxillary
puncture and
endoscopic
sampling
2 Vandenbuscsche
/200022
General
ICU
Retrospective
cohort/SC
Pts on
prolonged MV
53b CT Cultures
obtained by
maxillary
puncture and
endoscopically
NR NR Reported on the
efficacy and
safety of
maxillary
puncture
3 Le Moal/199324 Medical
ICU
Retrospective
cohort/SC
Pts treated
in ICU > 48 h
30c CT/SXR Quantitative;
cultures
obtained by
maxillary
puncture
NR NR Reported on the
incidence of
anaerobic
sinus infections
in critically ill
4 Bert/199530 Medicale
Surgical
ICUs
Retrospective
cohort/SC
Retrospective
cohort/SC
4509 NR Cultures
obtained by
maxillary
puncture
NR 107/4509 (2) Reported on
the microbiological
sinus finding in
patients with C-VAS
Abbreviations: CT: computerized tomography; C-VAS: clinical ventilator-associated sinusitis; ICU: intensive care unit; MV: mechanic ntilation; NR: not reported; Pts: patients; R-VAS:
radiographic ventilator-associated sinusitis; SC: single center; SXR: sinus x-ray.
Notes:
a Two patients were not on MV.
b Three patients were not on MV.
c Four patients were not on MV.
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Study or Subgroup
Rouby 1994
Michelson 1992
Holzapfel 1993
Bach 1992
Total (95% CI)
Total events
Heterogeneity: Tau² = 1.06; Chi² = 12.13, df = 3 (P = 0.007); I² = 75%
Test for overall effect: Z = 2.43 (P = 0.02)
Events
21
19
45
25
110
Total
22
20
149
36
227
Events
5
15
33
15
68
Total
18
24
151
32
225
Weight
16.8%
17.5%
35.3%
30.4%
100.0%
M-H, Random, 95% CI
54.60 [5.72, 520.99]
11.40 [1.30, 100.25]
1.55 [0.92, 2.60]
2.58 [0.95, 6.95]
4.66 [1.35, 16.13]
Nasotracheal Orotracheal Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Higher in OTI Higher in NTI
Figure 2 R-VAS in nasotracheally versus orotracheally intubated critically ill patients. Abbreviations: R-VAS: radiographic
ventilator-associated sinusitis; OTI: orotracheal intubation; NTI: nasotracheal intubation; MeH: ManteleHaenszel.
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pneumonia (VAP)
According to the data provided by 10 studies (326 patients
with C-VAS) VAP was present in 41% of adult critically ill
patients with C-VAS.13,15,23e25,27,28,31,34,41 In addition, 4
studies reported data on the frequency of VAP and C-VAS;
the presence of VAP was higher in patients with C-VAS than
in patients without C-VAS (OR: 3.66, 95% CI [1.81, 7.37],
I2 Z 58%) (Fig. 4).13,25,31,34 Of note, comparisons between
the baseline characteristics of patients with and without
VAS were not available in any of the included reports.
Moreover, the same pathogen was isolated from culture
specimens of the lungs and sinuses in 59% of patients (10
studies, 147 patients).13,15,16,23e25,27,31,34,39 In the study by
Holzapfel et al., the incidence of VAP was lower in the
group of patients who underwent systemic investigation for
diagnosis and treatment of VAS (77 vs. 34%; p Z 0.02).25
Relationship of VAS to bloodstream infections
Two studies25,34 provided data on the development of
bloodstream infections in patients with C-VAS as compared
to patients without C-VAS. When the results were pooled,
more bloodstream infections were reported in patients with
C-VAS than patients without C-VAS (OR 6.85, CI 2.14e21.92,
I2Z 77%) (Fig. 5).25,34 Neither of these two studies provided
comparisons of the baseline characteristics of patients with
and without C-VAS. In addition, the same pathogen was
isolated from blood and culture specimens of sinuses in 20%Study or Subgroup
Michelson 1992
Holzapfel 1993
Bach 1992
Total (95% CI)
Total events
Heterogeneity: Tau² = 1.37; Chi² = 8.59, df = 2 (P = 0.01); I² = 77%
Test for overall effect: Z = 1.67 (P = 0.09)
Events
7
29
15
51
Total
20
149
36
205
Events
2
25
2
29
Total
24
151
32
207
Weight
28.4%
41.5%
30.1%
100.0%
Nasotracheal Orotracheal
Figure 3 C-VAS in nasotracheally versus orotracheally intubated
associated sinusitis; OTI: orotracheal intubation; NTI: nasotracheaof patients (5 studies, 181 patients).25,30,34,41,43 It should be
mentioned that in the study by Holzapfel et al the same
pathogen was isolated from sinus fluid, bronchoalveolar
lavage and blood cultures in 7 out of 54 patients with C-
VAS.34 Last, in a Cox model which treated C-VAS as a time
dependent factor, the presence of C-VAS, as compared to
its absence, significantly increased the risk of bloodstream
infection by 2.29 (95% CI 1.10e4.74).25Relationship of VAS to other infections
Concomitant infectious causes of fever in patients with C-
VAS (ostensibly not related to the presence of C-VAS)
included urinary tract, abdominal and central catheter
infections.17,32,41,42 Central nervous system infections,
either as primary events or as complications of C-VAS have
also been reported.32,41,42Prevention
Five eligible articles reported on the impact of preventive
measures on the incidence of C-VAS and R-VAS (Table
4).14,16,18,19,33 Only 1 of them was specifically designed to
assess the impact of preventing measures specifically tar-
geting on C-VAS.16 In detail, Pneumatikos et al. randomized
trauma surgical patients to receive either a nasal xylome-
tazoline solution for 14 days (supplemented by nasal
budesonide after the first week) or placebo.16 They repor-
ted a non-significant lower incidence of C-VAS in the studyM-H, Random, 95% CI
5.92 [1.07, 32.90]
1.22 [0.67, 2.20]
10.71 [2.21, 51.88]
3.67 [0.80, 16.86]
Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Higher in OT Higher in NT
critically ill patients. Abbreviations: C-VAS: clinical ventilator-
l intubation; MeH: ManteleHaenszel.
Study or Subgroup
Cengiz 2009
Holzapfel 1993
Holzapfel 1999
Rouby 1994
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.29; Chi² = 7.12, df = 3 (P = 0.07); I² = 58%
Test for overall effect: Z = 3.62 (P = 0.0003)
Events
8
16
23
29
76
Total
13
54
80
43
190
Events
13
10
14
23
60
Total
27
245
119
53
444
Weight
16.8%
26.5%
29.6%
27.1%
100.0%
M-H, Random, 95% CI
1.72 [0.45, 6.64]
9.89 [4.18, 23.41]
3.03 [1.45, 6.33]
2.70 [1.17, 6.24]
3.66 [1.81, 7.37]
C-VAS Absence of C-VAS Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Higher in no C-VAS Higher in C-VAS
Figure 4 Incidence of VAP in patients with C-VAS as opposed to patients with absence of C-VAS. Abbreviations: C-VAS: clinical
ventilator-associated sinusitis; OTI: orotracheal intubation; NTI: nasotracheal intubation; VAP: ventilator-associated pneumonia;
MeH: ManteleHaenszel.
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p Z 0.11).
A randomized controlled trial demonstrated a signifi-
cantly lower incidence of C-VAS in patients treated with
selective digestive tract decontamination (polymyxin E,
tobramycin, amphotericin B via the gastric tube plus oral
vancomycin) as compared to placebo (3 vs. 15%,
p < 0.02).33 On the other hand, another randomized
controlled trial compared the incidence of ICU-acquired
infections between patients treated with a selective
digestive tract decontamination regimen combining poly-
myxin E/tobramycin (delivered nasally, oropharyngeally
and via the gastric tube) with mupirucin (applied nasally)
and chlorexidine (body washing) and patients receiving
either regimen alone or placebo and demonstrated a lower
incidence of C-VAS in the study group (2.3 vs. 6.2 vs. 5.4 vs.
3.2%, respectively).18
In the study by Schweickert et al.19 the incidence of
critical illness-related complications between patients
managed with daily interruption of sedative effusions and
those managed with a physician-driven sedation protocol
were compared; none of the 66 patients in the intervention
group developed C-VAS, compared to 1 out of 60 patients in
the study group.19 Finally, a non-significant lower incidence
of R-VAS was reported for patients managed with bridled
compared to patients managed with unbridled feeding
tubes.14
Mortality
Two studies reported on the mortality of patients with C-
VAS as compared to patients with absence of C-VAS.23,42Study or Subgroup
Holzapfel 1993
Holzapfel 1999
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.55; Chi² = 4.44, df = 1 (P = 0.04); I² = 77%
Test for overall effect: Z = 3.24 (P = 0.001)
Events
21
24
45
Total
54
80
134
Events
12
12
24
Total
246
119
365
Weigh
49.5%
50.5%
100.0%
C-VAS Absence of C-VAS
Figure 5 Incidence of bloodstream infections in patients with C
tions: C-VAS: clinical ventilator-associated sinusitis; MeH: ManteleWhen the findings of these 2 studies were pooled, the
presence as opposed to absence of C-VAS was not associ-
ated with excess mortality (OR: 1.02, 95% CI [0.35, 3.01],
I2 Z 60%) (Fig. 6). However it should be noted that differ-
ences between patients with and without sinusitis might
have influenced mortality statistics. In particular, in the
report by Grindlinger et al., patients without VAS had
a significantly higher incidence of impaired level of
consciousness as compared to patients without VAS.42
On the other hand, in the randomized controlled trial by
Holzapfel et al.25 a significantly improved two-month
mortality was demonstrated for the group of patients who
underwent systemic investigation and treatment for C-VAS
versus the group of patients who received standard care (36
vs. 46%; p Z 0.03, log-rank test; RR Z 0.71, 95% CI [0.52,
0.97]); however it is worth mentioning that in the same
study a significantly lower incidence of VAP was also
observed for the study group.
Discussion
In this systematic review and meta-analysis we evaluated
and synthesized data from 31 studies focusing on sinusitis in
mechanically ventilated patients. Radiographically proved
accumulation of fluid within the sinuses affects more than
half of intubated patients; in turn, half of patients with R-
VAS will be eventually diagnosed with clinical infection of
the paranasal sinuses. In addition, C-VAS is not an
uncommon cause of fever of unidentified origin in critically
ill patients, and the infection is often polymicrobial.
Moreover we observed a significant association between C-
VAS and VAP or bloodstream infections. Last, presence ast M-H, Random, 95% CI
12.41 [5.59, 27.55]
3.82 [1.78, 8.21]
6.85 [2.14, 21.92]
Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Higher in no C-VAS Higher in C-VAS
-VAS as opposed to patients with absence of C-VAS. Abbrevia-
Haenszel.
Study or Subgroup
Grindlinger1987
Suweine 2000
Total (95% CI)
Total events
Heterogeneity: Tau² = 1.03; Chi² = 2.81, df = 1 (P = 0.09); I² = 64%
Test for overall effect: Z = 0.10 (P = 0.92)
Events
4
9
13
Total
19
15
34
Events
32
3
35
Total
92
9
101
Weight
56.4%
43.6%
100.0%
M-H, Random, 95% CI
0.50 [0.15, 1.63]
3.00 [0.53, 16.90]
1.09 [0.19, 6.23]
Mortality in C-VAS Mortality in no C-VAS Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Absence of C-VAS Presence of C-VAS
Figure 6 Mortality in critically ill patients with C-VAS as opposed to patients with absence of C-VAS. Abbreviations: C-VAS:
clinical ventilator-associated sinusitis; MeH: ManteleHaenszel.
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excess mortality.
We have observed a significant variability in the
frequency of VAS reported by the various eligible papers.
This discrepancy could partly be attributed to differences
in patient populations, and inclusion criteria (e.g. patients
with facial trauma or previous history of sinus disease), the
choice of radiographic screening method, as well as the
preferred route of tracheal and gastric intubation.2
Importantly, we were able to identify two types of inves-
tigations: those in which the presence of C-VAS is actively
searched according to a predefined investigation protocol
and those in which the diagnosis of C-VAS is considered in
critically ill patients scrutinized for fever of undetermined
origin. With respect to the second category of studies and
since C-VAS commonly coexists and is probably interrelated
with other infectious complications in the critically ill, (i.e.
VAP and bloodstream infections) it is quite possible that the
diagnosis might be missed when a more apparent source of
fever is present. Moreover, inasmuch the same pathogen
causing VAP and bloodstream infection is not uncommonly
also implicated in the pathogenesis of sinus infections, it is
likely that treatment of these alternative sources of fever
might also lead to resolution of C-VAS symptoms.
Not surprisingly, nasal instrumentation was the first
factor implicated as a potential cause of sinus infections in
mechanically ventilated critically ill patients.1 However,
according to the results of this meta-analysis radiographic
evidence of accumulation of fluid within the sinuses (i.e. R-
VAS), but not confirmed clinical infection, is more likely in
patients managed with nasotracheal/gastric intubation
than orotracheal/gastric intubation. Apparently, as sug-
gested by experimental evidence, the presence of a tube
within the nostrils creates an ostial obstruction which
facilitates accumulation of fluid within the sinus cavity and
subsequent inflammation.45 In addition, it is possible that
nasal tubes may act as locuses for biofilm formation which
in its turn might enhance upper airway colonization and
predispose to C-VAS.46,47 On the other hand the absence of
nasal tubes does not preclude the possibility of paranasal
sinus infection.34 Other risk factors should be considered as
well: anatomic variations or patient position may compro-
mise ostial size48,49; and sepsis-induced inhibition of nitric
oxide synthesis in the maxillary sinuses could impair
mucociliary clearance and epithelium perfusion.50
The results of this study reinforce previous views sug-
gesting a correlation between VAS and VAP in critically ill
patients.3 VAP affects four out of ten patients with docu-
mented C-VAS; importantly, presence as opposed toabsence of C-VAS is associated with a higher risk of VAP.
Also, in the majority of patients with concurrent C-VAS and
VAP the same pathogen is implicated in approximately 60%
of both infectious processes. From this point of view
a direct causal association between the two processes
might be considered. On the other hand, these findings
maybe a mere reflection of similarities in pathogenetic
mechanisms related to the presence of the tube which
bypasses physical barriers and impairs secretion clearance
or could indicate identical patterns of upper and lower
airway colonization.46,47 Moreover, the temporal relation-
ship between C-VAS and VAP episodes is not explicitly
reported in the majority of the eligible studies. However it
worth mentioning that the incidence of VAP is lower in
patients in whom a protocol of active investigation and
treatment for C-VAS is applied.25
In a similar manner, the frequency of bloodstream
infections is higher in C-VAS and in a significant minority of
patients with C-VAS the same pathogen was isolated from
the sinuses and blood cultures. However this association
maybe moderated by the frequent coexistence of VAP in
patients with C-VAS or could be again related to similarities
of pathogens colonizing epithelial surfaces in critically ill
patients.34 However, it is not unlikely that some cases of
primary bloodstream infections might be in fact related to
an undiagnosed C-VAS.
There is relative paucity of evidence pertaining to pre-
ventional measures against C-VAS. The only study that was
specifically designed to assess that issue showed a non-
significant lower incidence of C-VAS for patients treated
with nasal decongestants and steroids, which did not reach
statistical significance.16 The potential of other interven-
tions, notably selective digestive tract decontamination,
remains largely unexplored.
Considering the abovementioned facts, a key question,
whether C-VAS represents a true cause of excess mortality in
critically ill patients remains to be answered. The results of
thismeta-analysis,which involveda limited number of cases,
suggest the patientswith C-VAS do not carry an increased risk
of death. While considering the issue of C-VAS attributable
mortality, we should bear in mind the frequent coexistence
of other infectious processes in patients with C-VAS, some of
them (notably VAP) exerting a significant impact on patient
outcome.10,12 Therefore, although a strategy of active
search and treatment of C-VAS has been associated with
a lowermortality, itmust benoted that this strategy also lead
to a lower VAP incidence.25
This review has some limitations. First, varying clinical
and, most importantly, radiologic diagnostic strategies were
1094 M. Agrafiotis et al.employed in the individual studies for the diagnosis of VAS.
Importantly, in many cases the diagnosis of R-VAS could be
biased, since sinus fluid might have already been present
preceding patient admission to ICU. In addition, the involved
populations of patients exhibited significant variability
regarding primary disease, previous history (including
history of facial trauma and sinus disease) and clinical
characteristics. For the abovementioned reasons the calcu-
lated incidence of VAS in mechanically ventilated patients
should be considered merely an approximation. Also,
statistical heterogeneity might influence the interpretation
of our findings. However, this is a common limitation in
meta-analyses on ventilator-associated infections.10,51e53
Last, a fact that might limit the interpretation of the
meta-analyses of this review is the paucity of data on the
baseline characteristics of patients with and without C-VAS.
Despite the abovementioned limitations, the findings of
this review offer some valuable clinical insights. C-VAS
affects almost one fourth of mechanically ventilated
patients and is a common cause of subtle fever in critically
ill patients. In addition C-VAS bears a correlation with other
significant infections, as VAP and bloodstream infections.Conflict of interest
None declared.
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